Fuji Pharma Co.,Ltd.
4554 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 千代田区三番町５番地７
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Fuji Pharma Co., Ltd. is a prominent Japanese pharmaceutical company dedicated to developing and manufacturing high-quality medications. With a strong emphasis on research and innovation, the company focuses on therapeutic areas such as infectious diseases, metabolic disorders, and oncology. Fuji Pharma is committed to enhancing global healthcare through its diverse portfolio of products, which includes both prescription and over-the-counter medications. The company adheres to stringent quality standards and regulatory compliance to ensure the safety and efficacy of its offerings. With a vision to improve patient outcomes, Fuji Pharma continues to invest in advanced technologies and collaborations, striving to meet the evolving needs of patients and healthcare professionals worldwide.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-09 04:10 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2025-05-09 04:09 |
Interim Report
半期報告書－第61期(2024/10/01－2025/09/30)
|
Japanese | 216.6 KB | |
| 2024-12-23 04:46 |
Inside Information Statement
臨時報告書
|
Japanese | 25.0 KB | |
| 2024-12-23 04:37 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2024-12-23 04:33 |
Internal Control over Financial Reporting
内部統制報告書－第60期(2023/10/01－2024/09/30)
|
Japanese | 23.3 KB | |
| 2024-12-23 04:32 |
Annual Report
有価証券報告書－第60期(2023/10/01－2024/09/30)
|
Japanese | 1.7 MB | |
| 2024-07-18 09:11 |
Prospectus
有価証券届出書（参照方式）
|
Japanese | 285.7 KB | |
| 2024-05-10 07:27 |
Quarterly Report
四半期報告書－第60期第2四半期(2024/01/01－2024/03/31)
|
Japanese | 216.0 KB | |
| 2024-05-10 07:27 |
Regulatory News Service
確認書
|
Japanese | 8.6 KB | |
| 2024-02-09 08:20 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2024-02-09 08:19 |
Quarterly Report
四半期報告書－第60期第1四半期(2023/10/01－2023/12/31)
|
Japanese | 178.7 KB | |
| 2023-12-21 07:28 |
Inside Information Statement
臨時報告書
|
Japanese | 27.9 KB | |
| 2023-12-21 07:26 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2023-12-21 07:25 |
Internal Control over Financial Reporting
内部統制報告書－第59期(2022/10/01－2023/09/30)
|
Japanese | 23.3 KB | |
| 2023-12-21 07:23 |
Annual Report
有価証券報告書－第59期(2022/10/01－2023/09/30)
|
Japanese | 1.6 MB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
AnGes, Inc. | Japan | 4563 |